Technology transfer portfolio
Six platforms. One purpose: building the expertise, systems and infrastructure for local capability.
6of 6 platforms ·0selected for comparison.Select up to three to compare.
Advanced genomic testing platforms for precision oncology, inherited disease analysis, pathogen sequencing, microbiome analysis and population-level genomic programmes.
Diagnostic testing is regulated differently in every jurisdiction. VectorGene supports local validation and accreditation; the regulatory dossier remains owned by the local institution.
End-to-end support for hospitals and biotechnology organisations to establish CAR-T manufacturing and clinical treatment capability, from GMP facility planning to first clinical use.
CAR-T therapies are approved in several markets for defined indications. Local manufacture and clinical use require approval from the national regulatory authority of the host country, which the local partner owns.
Clinical and translational platforms for immune cell therapy and cellular medicine, available for research collaboration or clinical implementation subject to local regulatory approval.
Most platforms in this group are investigational outside defined trial settings. VectorGene does not present investigational therapies as standard care, and every programme is designed around the host country regulatory framework.
Technology transfer and local implementation support for autologous HSPC gene therapy programmes for transfusion-dependent beta-thalassemia and sickle cell disease.
Gene therapies for beta-thalassemia and sickle cell disease are approved in some markets. Local delivery requires national regulatory clearance, ethics approval and long-term follow-up commitments, all owned by the local institution.
Metagenomic and targeted sequencing platforms for infectious disease diagnosis, outbreak surveillance and microbiome research at institutional or national scale.
Clinical use of metagenomic sequencing is regulated as a diagnostic and varies by jurisdiction. Surveillance and research applications typically sit under different frameworks.
Patient-derived organoid and stem cell platforms for drug screening, treatment response prediction and translational research collaboration.
These platforms are supported for research collaboration and translational study. They are not offered as clinical services, and results are not presented as a basis for treatment decisions outside a trial.
Illustrative licensed stock photography shows general working environments.
The six platforms represent different technical and institutional needs. Their timelines are supplied planning ranges, rather than guarantees. Compare the intended use and local baseline first, then read the capabilities and complete regulatory note for the platform you want to assess.
WHO’s laboratory quality handbook addresses management, administration and bench work together. It provides a foundation for organising a laboratory’s quality system; current accreditation requirements need to be checked separately.
WHO: Laboratory quality management system: handbookExternal references explain the wider context. They do not verify or endorse the supplied VectorGene or partner offering.
What local clinical, public-health or research need should the capability address?
Which workforce, facility, methods and quality systems can the programme build on?
What product-specific evidence and local pathway need to be confirmed?
Working environments
Illustrative stock photography provides context for the people, processes and working environments behind this capability.
Move through this field of pillars to explore how a change in one area reaches the surrounding system. The heights are illustrative.
Move across the drawing to explore.
